These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 33389277)

  • 1. Evaluation of Drug Dissolution Rate in Co-amorphous and Co-crystal Binary Drug Delivery Systems by Thermodynamic and Kinetic Methods.
    Hu C; Zhang F; Fan H
    AAPS PharmSciTech; 2021 Jan; 22(1):21. PubMed ID: 33389277
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of self-nanoemulsifying drug delivery system for oral bioavailability enhancement of valsartan in beagle dogs.
    Li Z; Zhang W; Gao Y; Xiang R; Liu Y; Hu M; Zhou M; Liu X; Wang Y; He Z; Sun Y; Sun J
    Drug Deliv Transl Res; 2017 Feb; 7(1):100-110. PubMed ID: 27812915
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of valsartan-loaded gelatin microcapsule without crystal change using hydroxypropylmethylcellulose as a stabilizer.
    Li DX; Yan YD; Oh DH; Yang KY; Seo YG; Kim JO; Kim YI; Yong CS; Choi HG
    Drug Deliv; 2010 Jul; 17(5):322-9. PubMed ID: 20367177
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Candesartan cilexetil loaded solid lipid nanoparticles for oral delivery: characterization, pharmacokinetic and pharmacodynamic evaluation.
    Dudhipala N; Veerabrahma K
    Drug Deliv; 2016; 23(2):395-404. PubMed ID: 24865287
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enhanced dissolution of valsartan-vanillin binary co-amorphous system loaded in mesoporous silica particles.
    Hashim Ali K; Mohsin Ansari M; Ali Shah F; Ud Din F; Abdul Basit M; Kim JK; Zeb A
    J Microencapsul; 2019 Jan; 36(1):10-20. PubMed ID: 30719944
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Single therapeutic and supratherapeutic doses of sacubitril/valsartan (LCZ696) do not affect cardiac repolarization.
    Langenickel TH; Jordaan P; Petruck J; Kode K; Pal P; Vaidya S; Chandra P; Rajman I
    Eur J Clin Pharmacol; 2016 Aug; 72(8):917-24. PubMed ID: 27083930
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Increasing the dissolution rate and oral bioavailability of the poorly water-soluble drug valsartan using novel hierarchical porous carbon monoliths.
    Zhang Y; Che E; Zhang M; Sun B; Gao J; Han J; Song Y
    Int J Pharm; 2014 Oct; 473(1-2):375-83. PubMed ID: 25051114
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Improved pH-independent dissolution and oral absorption of valsartan via the preparation of solid dispersion.
    Park YJ; Lee HK; Im YB; Lee W; Han HK
    Arch Pharm Res; 2010 Aug; 33(8):1235-40. PubMed ID: 20803127
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Co amorphous valsartan nifedipine system: Preparation, characterization, in vitro and in vivo evaluation.
    Lodagekar A; Chavan RB; Mannava MKC; Yadav B; Chella N; Nangia AK; Shastri NR
    Eur J Pharm Sci; 2019 Nov; 139():105048. PubMed ID: 31446077
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Sacubitril / Valsartan in patients with diabetes and heart failure].
    Brandenburg VM; Rocca HB; Marx N
    Dtsch Med Wochenschr; 2016 Oct; 141(22):1647-1649. PubMed ID: 27824422
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Melt dispersion granules: formulation and evaluation to improve oral delivery of poorly soluble drugs - a case study with valsartan.
    Chella N; Tadikonda R
    Drug Dev Ind Pharm; 2015 Jun; 41(6):888-97. PubMed ID: 24796274
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Amino acids as co-amorphous excipients for tackling the poor aqueous solubility of valsartan.
    Huang Y; Zhang Q; Wang JR; Lin KL; Mei X
    Pharm Dev Technol; 2017 Feb; 22(1):69-76. PubMed ID: 27050301
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacodynamic interaction between intravenous nitroglycerin and oral sacubitril/valsartan (LCZ696) in healthy subjects.
    Schuehly U; Ayalasomayajula S; Buchbjerg J; Pal P; Golor G; Prescott MF; Sunkara G; Hinder M; Langenickel TH
    Eur J Clin Pharmacol; 2018 Sep; 74(9):1121-1130. PubMed ID: 29974143
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetic drug-drug interaction assessment between LCZ696, an angiotensin receptor neprilysin inhibitor, and hydrochlorothiazide, amlodipine, or carvedilol.
    Hsiao HL; Langenickel TH; Greeley M; Roberts J; Zhou W; Pal P; Rebello S; Rajman I; Sunkara G
    Clin Pharmacol Drug Dev; 2015 Nov; 4(6):407-17. PubMed ID: 27137712
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Soluplus®/TPGS-based solid dispersions prepared by hot-melt extrusion equipped with twin-screw systems for enhancing oral bioavailability of valsartan.
    Lee JY; Kang WS; Piao J; Yoon IS; Kim DD; Cho HJ
    Drug Des Devel Ther; 2015; 9():2745-56. PubMed ID: 26045660
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Angiotensin-Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction.
    Solomon SD; McMurray JJV; Anand IS; Ge J; Lam CSP; Maggioni AP; Martinez F; Packer M; Pfeffer MA; Pieske B; Redfield MM; Rouleau JL; van Veldhuisen DJ; Zannad F; Zile MR; Desai AS; Claggett B; Jhund PS; Boytsov SA; Comin-Colet J; Cleland J; Düngen HD; Goncalvesova E; Katova T; Kerr Saraiva JF; Lelonek M; Merkely B; Senni M; Shah SJ; Zhou J; Rizkala AR; Gong J; Shi VC; Lefkowitz MP;
    N Engl J Med; 2019 Oct; 381(17):1609-1620. PubMed ID: 31475794
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Continuous manufacturing of co-crystals: challenges and prospects.
    Chavan RB; Thipparaboina R; Yadav B; Shastri NR
    Drug Deliv Transl Res; 2018 Dec; 8(6):1726-1739. PubMed ID: 29352367
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combined Angiotensin Receptor Antagonism and Neprilysin Inhibition.
    Hubers SA; Brown NJ
    Circulation; 2016 Mar; 133(11):1115-24. PubMed ID: 26976916
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effect of angiotensin receptor neprilysin inhibitor, sacubitril/valsartan, on central nervous system amyloid-β concentrations and clearance in the cynomolgus monkey.
    Schoenfeld HA; West T; Verghese PB; Holubasch M; Shenoy N; Kagan D; Buono C; Zhou W; DeCristofaro M; Douville J; Goodrich GG; Mansfield K; Saravanan C; Cumin F; Webb RL; Bateman RJ
    Toxicol Appl Pharmacol; 2017 May; 323():53-65. PubMed ID: 28315356
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of Pharmacokinetic and Pharmacodynamic Drug-Drug Interaction of Sacubitril/Valsartan (LCZ696) and Sildenafil in Patients With Mild-to-Moderate Hypertension.
    Hsiao HL; Langenickel TH; Petruck J; Kode K; Ayalasomayajula S; Schuehly U; Greeley M; Pal P; Zhou W; Prescott MF; Sunkara G; Rajman I
    Clin Pharmacol Ther; 2018 Mar; 103(3):468-476. PubMed ID: 28599060
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.